Latest News & Updates

FDA approves new and updated indications for temozolomide under Project Renewal
September 14, 2023

Continue Reading »

FDA approves melphalan as a liver-directed treatment for uveal melanoma
August 15, 2023

Continue Reading »

FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer
August 11, 2023

Continue Reading »

FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma
August 10, 2023

Continue Reading »

FDA approves new and updated indications for temozolomide under Project Renewal
September 14, 2023

Continue Reading »

FDA approves melphalan as a liver-directed treatment for uveal melanoma
August 15, 2023

Continue Reading »

FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer
August 11, 2023

Continue Reading »

FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma
August 10, 2023

Continue Reading »

Get More from FLASCO With Your Partnership

The Corporate Partnership Program allows FLASCO to expand our offerings to our partneres. Every FLASCO meeting also provides the industry representative with opportunities to educate our partners. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Partners

Diamond Elite

Diamond

Platinum

Gold

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: